DOI: https://doi.org/10.24026/1818-1384.3(44).2013.77778

Метаболічний вплив метформіну та піоглітазону на тиреоїдний статус, вуглеводний і ліпідний обмін у хворих на гіпотиреоз з інсулінорезистентністю

Х. А. Москва, Л. Є. Лаповець, О. П. Кіхтяк

Анотація


Comparative data between metformin and pioglitazone are described in this paper taking into account their action on thyroid panel, carbohydrate and lipid metabolism in patients with hypothyroidism, established insulin resistance on the base of replacement treatment with levothyroxine. Treatment duration was 6 months, where first 3 months were dedicated to achieve euthyroidism, while the last period of time was given to carry out combination of levothyroxine with pioglitazone or metformin. It was recorded that metformin significantly decreases glycated hemoglobin and fasting glucose. Instead of this, pioglitazone significantly diminished fasting insulin, C-peptide and with resulted descent of HOMA-β and increased Karo index. Comparison of drugs showed that metformin decreased thyroid stimulating hormone and pioglitazone significantly increased the level of free thyroxine and triiodothyronine. 


Ключові слова


metformin; pioglitazone; insulin resistance; hypothyroidism; levothyroxine

Повний текст:

PDF

Посилання


Боровиков В. STATISTICA: Искусство анализа данных на компьютере. Для профессионалов / В. Боровиков – СПб.: Питер, 2001. – 656 с.

Особливості ліпідного та вуглеводного обмінів у хворих з метаболічним синдромом та дисфункцією щитоподібної залози / А.О. Логвиненко, О.І. Мітченко, В.Ю. Романов [та ін.] // Український кардіологічний журнал. – 2009. – № 4. – С. 34-39.

Alevizaki M. Metformin and thyroid: some questions still remain // M. Alevizaki // Clin. Endocrinol. (Oxf). – 2013. – Vol. 78, №4. – P. 503-504. https://doi.org/10.1111/cen.12005

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial / A.S. Kelly, R.M. Bergenstal, J.M. Gonzalez-Campoy [et al.] // Cardiovascular Diabetology. – 2012. – Vol. 11, №64. – P. 121-128. https://doi.org/10.1186/1475-2840-11-64

Hirst J.A. Quantifying the effect of metformin treatment and dose on glycemic control. / J.A. Hirst, A.J. Farmer, R. Ali // Diabetes Care. – 2012. – Vol. 35, №2. – P. 446-454. https://doi.org/10.2337/dc11-1465

Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy / M.L. Isidro, M.A. Penin, R. Nemina, F. Cordido // Endocrine. – 2007. – Vol. 32, №1. – P. 79-82. https://doi.org/10.1007/s12020-007-9012-3

Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity / A. Marsili, C. Aguayo-Mazzucato, T. Chen [et al.] // PLoS One. – 2011. – Vol. 6, №6. – P. 208-232. https://doi.org/10.1371/journal.pone.0020832

Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. / W.T. Festuccia, S. Oztezcan, M. Laplante [et al.] // Endocrinology. – 2008. – Vol. 149, №5 – P. 2121-2130. https://doi.org/10.1210/en.2007-1553

Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, mechanistic study / D. Tripathy, G. Daniele, T.V. Fiorentino [et al.] // Diabetologia. – 2013. – Vol. 30. – P. 1457-1475. https://doi.org/10.1007/s00125-013-2976-z

Studies of insulin resistance in patients with clinical and subclinical hypothyroidism / E. Maratou, D.J. Hadjidakis, A. Kollias [et al] // European Journal of Endocrinology. – 2009. – Vol. 160. – P. 785-790. https://doi.org/10.1530/eje-08-0797

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial / M. Razavizade, R. Jamali, A. Arj [et al.] // Hepat. Mon. – 2013. – Vol. 13, №5 – P. 9270-9280. https://doi.org/10.5812/hepatmon.9270

TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. / C. Cappelli, M. Rotondi, I. Pirola [et al.] // Diabetes Care. – 2009. – Vol. 32, №9. – P. 1589-1590. https://doi.org/10.2337/dc09-0273

Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes / R. Grozovsky, S. Ribich, M.L. Rosene [et al.] // Endocrinology. – 2009. – Vol. 150, №4. – P. 1976-1983. https://doi.org/10.1210/en.2008-0938

Quantifying the effect of metformin treatment and dose on glycemic control / J.A. Hirst, A.J. Farmer, R. Ali [et al.] // Diabetes Care. – 2012. – Vol. 35, №2. – P. 446-454. https://doi.org/10.2337/dc11-1465


Пристатейна бібліографія ГОСТ








Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter